氧化应激
髓系白血病
干细胞
癌症研究
白血病
医学
髓样
癌症干细胞
癌症
免疫学
生物信息学
生物
内科学
细胞生物学
作者
Rafaela G.A. Costa,Suellen L R Silva,Ingrid Rayssa Souza Baliza Dias,Maiara de Souza Oliveira,Ana Carolina Rodrigues,Rosane Borges Dias,Daniel Pereira Bezerra
出处
期刊:Redox biology
[Elsevier]
日期:2023-06-01
卷期号:62: 102692-102692
被引量:5
标识
DOI:10.1016/j.redox.2023.102692
摘要
Acute myeloid leukemia (AML) is a very heterogeneous group of disorders with large differences in the percentage of immature blasts that presently are classified according to the specific mutations that trigger malignant proliferation among thousands of mutations reported thus far. It is an aggressive disease for which few targeted therapies are available and still has a high recurrence rate and low overall survival. The main reason for AML relapse is believed to be due to leukemic stem cells (LSCs) that have unlimited self-renewal capacity and long residence in a quiescent state, which promote greater resistance to traditional therapies for this cancer. AML LSCs have low oxidative stress levels, which appear to be caused by a combination of low mitochondrial activity and high activity of ROS-removing pathways. In this sense, oxidative stress has been thought to be an important new potential target for the treatment of AML patients, targeting the eradication of AML LSCs. The aim of this review is to discuss some drugs that induce oxidative stress to direct new goals for future research focusing on redox imbalance as an effective strategy to eliminate AML LSCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI